Table 2

Pathways commonly deregulated in colorectal cancer and targeted drugs in clinical use (in bold) or in clinical trials

PathwaySpecific targetDrugs
EGF/MAPKEGFR (mAb)Cetuximab, Panitumumab
EGFR (TKI)Erlotinib, Gefitinib
KRASTipifarnib, Lonafarnib
BRAFSorafenib, PLX4032, XL281
MEKSelumetinib
PI3KPI3KBKM120, BGT226, XL147, GDC-0941
mTOREverolimus, XL765
AKTPerifosine
WNTResveratrol
TGFβTGFβ2AP 12009
VEGFVEGFBevacizumab
VEGFRVatalanib, AMG706, Pazopanib, Cediranib
HGFHGF mAbAMG102
IGFIGF-1 mAbAMG479, IMC-A12
  • EGF, epidermal growth factor; HGF, hepatocyte growth factor; IGF, insulin-like growth factor; mAb, monoclonal antibody; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; TGFβ, transforming growth factor β; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.